1998
DOI: 10.1038/sj.onc.1201513
|View full text |Cite
|
Sign up to set email alerts
|

The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
22
0

Year Published

1998
1998
2006
2006

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 20 publications
(22 citation statements)
references
References 33 publications
(37 reference statements)
0
22
0
Order By: Relevance
“…Recently it has been reported that the J domain of T antigen is required for synergistic transactivation and binding with the transcription factor complex Tst-1-Oct6-SCIP (41). Others have shown that expression of a J domain-containing fragment of T antigen is sufficient to downregulate the Her-2 promoter, which is hyperactivated in certain breast cancers (26). Mutations in the J domain of T antigen render SV40 defective for viral DNA replication and virion assembly as well as transformation (32,42).…”
Section: Discussionmentioning
confidence: 99%
“…Recently it has been reported that the J domain of T antigen is required for synergistic transactivation and binding with the transcription factor complex Tst-1-Oct6-SCIP (41). Others have shown that expression of a J domain-containing fragment of T antigen is sufficient to downregulate the Her-2 promoter, which is hyperactivated in certain breast cancers (26). Mutations in the J domain of T antigen render SV40 defective for viral DNA replication and virion assembly as well as transformation (32,42).…”
Section: Discussionmentioning
confidence: 99%
“…13 Repression of the HER-2 function suppresses the malignant phenotypes of HER-2 overexpressing cancer cells. 14,15 The HER-2 protein is frequently overexpressed in bladder cancer. 16 -21 Our previous study and those of others indicated an association between the increased expression of the HER-2 protein and advanced tumor stage, grade and poor patient survival.…”
mentioning
confidence: 99%
“…While our studies were in progress, Kao et al (1998) reported that a deletion mutant of large T, T178, which contains only N-terminal 178 amino acids of large T, also down-regulates HER-2/neu expression and suppresses the tumorigenicity of the HER-2/neu-overexpressing ovarian carcinoma cells. These results suggest that large T and its derivative T178 may be considered as targeting agents for the treatment of HER-2/neu-overexpressing cancers Kao et al, 1998).…”
Section: Discussionmentioning
confidence: 84%
“…While our studies were in progress, Kao et al (1998) reported that a deletion mutant of large T, T178, which contains only N-terminal 178 amino acids of large T, also down-regulates HER-2/neu expression and suppresses the tumorigenicity of the HER-2/neu-overexpressing ovarian carcinoma cells. These results suggest that large T and its derivative T178 may be considered as targeting agents for the treatment of HER-2/neu-overexpressing cancers Kao et al, 1998). However, a serious concern exists as large T is also a potent viral oncoprotein which can fully transform cells in culture and induce tumors in nude and transgenic mice (Tooze, 1981;Srinivasan et al, 1989;SaÈ enz Robles et al, 1994;Tevethia et al, 1997).…”
Section: Discussionmentioning
confidence: 84%
See 1 more Smart Citation